A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

Status:
Active, not recruiting

Trial end date:
2024-11-05

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the efficacy of combination therapy with nipocalimab and certolizumab compared to certolizumab monotherapy.

Phase 2

Janssen Research & Development, LLC

Certolizumab Pegol